ABRs. ABRs (bleeding episodes on last dose level) during the main part in (A) explorer4 (HAwI/HBwI), (B) explorer5 (HA without inhibitors), and (C) by hemophilia type in explorer4 and explorer5 (HA, HAwI, HBwI). ABRs were calculated based on a negative binomial regression model with log of exposure time in the main part of the trials as offset and treatment arm as factor. (A) Bleed reduction for treatment with rFVIIa vs concizumab was 78%, 88%, and 79% for all treated bleeds and for spontaneous and joint bleeds, respectively; ***P < .001. (B) Observations from the 2-week run-in are not included. In explorer4, there was 1 medication error in which a patient unintentionally received 5 × 15 mg/kg concizumab.